Long-Term Favorable Results by Arteriovenous Graft with Omniflow II Prosthesis for Hemodialysis

Abstract

&lt;i&gt;Aims and Methods:&lt;/i&gt; In order to decrease arteriovenous graft (AVG) failure and improve long-term patency, we used Omniflow II to perform AVG for hemodialysis access in 38 patients with very compromised vessels who were not suitable for other forms of AVG. &lt;i&gt;Results:&lt;/i&gt; At a median follow-up of 38 (range 6–55) months, 31/38 (81%) patients were still alive. At 6, 12 ,18 and 24 months, primary patency was 92, 80, 68 and 60%, whereas secondary patency was 83, 80, 78 and 75%, respectively. The cumulative 38-month prosthetic AVG patency was 70%. No infective event related to the vascular prosthesis occurred. Neither AVG thrombosis nor modifications in thrombophilic pattern were observed; these findings confirm the high hemocompatibility of this prosthetic vascular device. &lt;i&gt;Conclusion:&lt;/i&gt; Our experience is extremely encouraging for the use of new biosynthetic devices such as Omniflow II.</jats:p